Gevo, Inc. current report, 21 June 2017

Business Context and Reporting Period

Gevo, Inc. filed this Form 8-K on June 21, 2017, regarding a notice received from The NASDAQ Stock Market LLC. The Company is incorporated in Delaware and maintains its principal executive offices in Englewood, Colorado.

Key Financial Metrics

This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.

Material Changes

The material event reported is the notification that the Company's common stock closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days. This triggers a potential delisting process under NASDAQ Listing Rule 5550(a)(2).

Outlook, Risks, and Management Commentary

  • Compliance Period: The Company has been granted an initial 180-day period, ending December 18, 2017, to regain compliance.
  • Compliance Requirement: To remain listed, the closing bid price must be $1.00 or more for at least 10 consecutive business days before the deadline.
  • Future Options: If compliance is not met by December 18, 2017, the Company may be eligible for an additional 180-day period if it meets other listing standards, potentially requiring a reverse stock split.
  • Risks: There is no assurance the Company will regain compliance or avoid delisting. If delisting occurs, the Company may appeal, but approval is not guaranteed.
  • Current Status: The notice has no immediate effect, and trading continues under the symbol "GEVO" on the NASDAQ Capital Market.

Investor Verification Checklist

  • Verify the current closing bid price of GEVO stock to assess proximity to the $1.00 threshold.
  • Monitor the Company's announcements regarding potential reverse stock splits or other capital structure changes.
  • Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if needed.
  • Check for any subsequent 8-K filings or press releases detailing the Company's specific plan to cure the deficiency.